 |
Robak Tadeusz; Jin Jie; Pylypenko Halyna; Verhoef Gregor; Siritanaratkul Noppadol; Drach Johannes; Raderer Markus; Mayer Jiri; Pereira Juliana; Tumyan Gayane; Okamoto Rumiko; Demeter Judit; Egyed Miklós; Borbényi Zita; et al.:
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
LANCET ONCOLOGY, 19 (11).
pp. 1449-1458.
ISSN 1470-2045
(2018)
![[Fel]](/style/images/multi_up.png)
Vissza
